Relative Impact of Monotherapies for Vitiligo: A Network Meta-Analysis Study

IF 2.5 4区医学 Q2 DERMATOLOGY Journal of Cosmetic Dermatology Pub Date : 2025-02-27 DOI:10.1111/jocd.70078

Aditya K. Gupta, Mary A. Bamimore, Julien Seneschal, Vincent Piguet, Mesbah Talukder

{"title":"Relative Impact of Monotherapies for Vitiligo: A Network Meta-Analysis Study","authors":"Aditya K. Gupta, Mary A. Bamimore, Julien Seneschal, Vincent Piguet, Mesbah Talukder","doi":"10.1111/jocd.70078","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Vitiligo, a stigmatizing condition characterized by patchy depigmented skin, has an estimated global prevalence of 0.36%. This condition is a risk factor for anxiety, depression, and even suicidal ideation. Hitherto, no network meta-analysis has investigated the relative effect of vitiligo on relevant monotherapies.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>The current study determined the relative effect of monotherapies for vitiligo through network meta-analyses (NMAs).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The peer-reviewed literature was systematically searched through PubMed and Scopus; studies that were eligible for quantitative analyses were those that were published in English and had an arm that investigated the effect of a monotherapy on vitiligo at 6 months. Studies of the randomized and observational designs were included.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The retrieved data were sufficient to analyze networks for phototherapy, Janus kinase inhibitors (JAKIs), calcineurin inhibitors, cyclosporine, corticosteroids, azathioprine, and minocycline. Modalities' effects, in each of the networks, were ranked with the surface under the cumulative ranking curve (SUCRA) metric; league tables were produced to depict agents' pairwise relative effects. Our secondary outcome was discontinuation due to any adverse event (AE) at 6 months.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>No significant differences are observed among JAK inhibitors; however, upadacitinib, cyclosporine, ritlecitinib, and dexamethasone are significantly more effective than minocycline. Psoralen (oral) + ultraviolet A (PUVA) and narrow band ultraviolet B (NB-UVB) regimens show similar efficacy for repigmentation. Ruxolitinib 1.5% cream (once or twice daily), ruxolitinib 0.5% cream once daily, and ruxolitinib 0.15% cream once daily for 6 months do not differ significantly in efficacy. Mometasone furoate and tacrolimus 0.1% ointment are more effective than tacrolimus 0.03%.</p>\n </section>\n </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"24 3","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.70078","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cosmetic Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70078","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Vitiligo, a stigmatizing condition characterized by patchy depigmented skin, has an estimated global prevalence of 0.36%. This condition is a risk factor for anxiety, depression, and even suicidal ideation. Hitherto, no network meta-analysis has investigated the relative effect of vitiligo on relevant monotherapies.

Aim

The current study determined the relative effect of monotherapies for vitiligo through network meta-analyses (NMAs).

Methods

The peer-reviewed literature was systematically searched through PubMed and Scopus; studies that were eligible for quantitative analyses were those that were published in English and had an arm that investigated the effect of a monotherapy on vitiligo at 6 months. Studies of the randomized and observational designs were included.

Results

The retrieved data were sufficient to analyze networks for phototherapy, Janus kinase inhibitors (JAKIs), calcineurin inhibitors, cyclosporine, corticosteroids, azathioprine, and minocycline. Modalities' effects, in each of the networks, were ranked with the surface under the cumulative ranking curve (SUCRA) metric; league tables were produced to depict agents' pairwise relative effects. Our secondary outcome was discontinuation due to any adverse event (AE) at 6 months.

Conclusions

No significant differences are observed among JAK inhibitors; however, upadacitinib, cyclosporine, ritlecitinib, and dexamethasone are significantly more effective than minocycline. Psoralen (oral) + ultraviolet A (PUVA) and narrow band ultraviolet B (NB-UVB) regimens show similar efficacy for repigmentation. Ruxolitinib 1.5% cream (once or twice daily), ruxolitinib 0.5% cream once daily, and ruxolitinib 0.15% cream once daily for 6 months do not differ significantly in efficacy. Mometasone furoate and tacrolimus 0.1% ointment are more effective than tacrolimus 0.03%.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

单一疗法对白癜风的相对影响：一项网络荟萃分析研究

白癜风是一种以皮肤斑点性脱色为特征的疾病，全球患病率约为0.36%。这种情况是焦虑、抑郁甚至自杀念头的危险因素。到目前为止，还没有网络荟萃分析调查白癜风对相关单一疗法的相对影响。目的本研究通过网络荟萃分析（NMAs）确定单一疗法治疗白癜风的相对效果。方法通过PubMed和Scopus系统检索同行评议文献；有资格进行定量分析的研究是那些用英语发表的研究，其中有一项研究是在6个月时调查单一疗法对白癜风的影响。纳入随机和观察设计的研究。结果检索到的数据足以分析光疗、Janus激酶抑制剂（JAKIs）、钙调磷酸酶抑制剂、环孢素、皮质类固醇、硫唑嘌呤和米诺环素的网络。在累积排序曲线（SUCRA）指标下，对每个网络中的模式效应与表面进行排序；制作排行榜是为了描述药剂的两两相对效应。我们的次要终点是在6个月时因任何不良事件（AE）而停药。结论JAK抑制剂间无显著性差异；然而，升级他替尼、环孢素、利来替尼和地塞米松明显比米诺环素更有效。补骨脂素（口服）+紫外线A （PUVA）和窄带紫外线B （NB-UVB）方案对色素重沉着的疗效相似。Ruxolitinib 1.5%乳膏（每日1次或2次），Ruxolitinib 0.5%乳膏每日1次，Ruxolitinib 0.15%乳膏每日1次，连续6个月疗效无显著差异。糠酸莫米松和0.1%他克莫司软膏比0.03%他克莫司更有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Cosmetic Dermatology DERMATOLOGY-

CiteScore

4.30

自引率

13.00%

发文量

818

审稿时长

>12 weeks

期刊介绍： The Journal of Cosmetic Dermatology publishes high quality, peer-reviewed articles on all aspects of cosmetic dermatology with the aim to foster the highest standards of patient care in cosmetic dermatology. Published quarterly, the Journal of Cosmetic Dermatology facilitates continuing professional development and provides a forum for the exchange of scientific research and innovative techniques. The scope of coverage includes, but will not be limited to: healthy skin; skin maintenance; ageing skin; photodamage and photoprotection; rejuvenation; biochemistry, endocrinology and neuroimmunology of healthy skin; imaging; skin measurement; quality of life; skin types; sensitive skin; rosacea and acne; sebum; sweat; fat; phlebology; hair conservation, restoration and removal; nails and nail surgery; pigment; psychological and medicolegal issues; retinoids; cosmetic chemistry; dermopharmacy; cosmeceuticals; toiletries; striae; cellulite; cosmetic dermatological surgery; blepharoplasty; liposuction; surgical complications; botulinum; fillers, peels and dermabrasion; local and tumescent anaesthesia; electrosurgery; lasers, including laser physics, laser research and safety, vascular lasers, pigment lasers, hair removal lasers, tattoo removal lasers, resurfacing lasers, dermal remodelling lasers and laser complications.